12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Afirma Gene Expression Classifier regulatory update

Veracyte said the New York State Department of Health licensed the use of the Afirma Gene Expression Classifier to reclassify ambiguous thyroid fine needle aspirate (FNA) samples as either benign or suspicious for cancer. New York is the only state...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >